Immunoglobulins Market
Immunoglobulins Market Study by Intravenous, Subcutaneous, and Intramuscular Administration for Neurology, Immunology, and Hematology from 2023 to 2033
Analysis of Immunoglobulins Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Immunoglobulins Market Outlook (2023 to 2033)
Global demand for immunoglobulins is predicted to increase at a CAGR of 6.8% from 2023 to 2033. The global immunoglobulins market is valued at US$ 14 billion in 2023 and is thus expected to reach US$ 27 billion by 2033-end. The use of immunoglobulins in hospitals is increasing because they facilitate the better supervision of patients who are undergoing infusions and are cost-effective.
An immunoglobulin, also known as an antibody, is a biologically generated protein by plasma cells and other lymphocytes that the immune system uses to identify and eliminate microorganisms that cause disease. Commercial immunoglobulin is a blood product that is fractionated and purified for use in therapeutic and research procedures.
The emergence of improved purification procedures that provide a higher yield of plasma and the increase in immunodeficiency disease prevalence are the key drivers of the worldwide market for immunoglobulins. Additionally, immunoglobulins help spatial genomic analysis provide a biomarker for cancer diagnostics, whose rising demand is anticipated to fuel the expansion of the immunoglobulins market. Another factor driving market growth is the usage of the products in the treatment of neurological illnesses.
It is anticipated that the market would rise due to advancements in the field of research and development for the development of new products for the control of diseases. The market for immunoglobulins is predicted to expand quickly as a result of rising immunoglobulin use and expanding research and development efforts.
Spatial information is being used as a diagnostic biomarker for a variety of diseases as a result of the identification of the spatial patterns of the genome for treating different medical problems. The need for more accurate biomarkers that can distinguish between benign and malignant tumors is growing, which is raising the demand for spatial genomic analysis as a cancer diagnostic tool. As a result, the growing need for reliable cancer diagnostic tools is contributing to market expansion.
Glycoproteins known as immunoglobulins are formed in the blood plasma. In turn, this response to body-present antigens. These immunoglobulins are given to patients with weakened immune systems. An illness such as immunodeficiency may be inherited by the body or result from exposure to infections through bodily fluids, chemotherapy, and cancer medications.
Fast food consumption is increasing among people as a result of increased urbanization and busy schedules. One of the main factors driving the growth of the market is this, along with sedentary lifestyles and a rise in patients with illnesses such as multiple myeloma, and autoimmune disorders.
Rising interest in customized treatment and increased awareness of the need for early diagnosis are further factors driving market expansion. Additionally, the body is assisted in fighting many infectious diseases by immunoglobulins through many administration methods. In addition, several pharmaceutical companies are releasing modern immunoglobulins for the treatment of neurological illnesses that are more effective and advanced.
Report Attributes |
Details |
|
Immunoglobulins Market Size (2023) |
US$ 14 Billion |
|
Projected Market Value (2033) |
US$ 27 Billion |
|
Global Market Growth Rate (2023 to 2033) |
6.8% CAGR |
|
Market Share of Intravenous Immunoglobulin Administration |
60% |
|
Key Companies Profiled |
|
Which are the Growth Determinants of the Market for Immunoglobulins?
“Increasing Prevalence of Immunological Disorders and Expanding Geriatric Population”
An increase in immunological disorders has led people to seek out advanced medical care, increasing the market share for immunoglobulins. The use of intravenous and subcutaneous immunoglobulins has significantly increased for off-label indications.
Global healthcare systems are extremely concerned about the growing senior population as well as the rising frequency of immunodeficiency and neurological illnesses. Thus, there is a rise in demand for novel intravenous immunoglobulin therapies due to increased awareness and the need to ensure effective treatment, which is anticipated to drive market revenue growth.
The market for immunoglobulins will experience significant expansion due to an increase in hemophiliac patients. The market for immunoglobulins may experience exponential expansion if immunoglobulin therapy becomes the preferred treatment for immunodeficiency and other rare neurological illnesses. Rapid regulatory approvals are also enhancing market growth potential.
Increasing prevalence of primary immunodeficiency disease (PID) around the world is another important factor influencing market expansion. In addition, the aging population, which is more susceptible to disease because their bodies have weak immune systems, is driving up the demand for immunoglobulin.
“Rapid Adoption of Innovative Immunoglobulin Therapies”
The adoption of innovative immunoglobulin therapies is increasing among medical professionals. It is regarded as the first line of treatment in patients with chronic inflammatory demyelinating polyneuropathy due to its efficacy.
There has been a rise in the demand for immunoglobulins as a therapy option due to higher awareness and an increase in diagnoses as a result of improved diagnostic techniques. Immunomodulation and anti-inflammatory characteristics of immunoglobulins are some other aspects that are assisting in the rise of the market for these substances.
The use of immunoglobulins is expanding, which is gaining traction among pharmaceutical and biopharmaceutical companies for immunoglobulin research and development. It is projected that an increase in intravenous product approvals and clinical trials for novel clinical uses would offer the industry substantial growth possibilities.
Market expansion is driven by high-tech healthcare facilities, rising public and private investments, growing usage of subcutaneous immunoglobulins, and surging popularity of enhanced immunotherapies. Increased financing for R&D projects and enhancing healthcare infrastructure are boosting market value.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What is Hampering the Demand for Immunoglobulins?
to be negatively impacted by the high cost of therapies. The market for immunoglobulins will face challenges from a lack of qualified personnel and the increased risk of adverse reactions associated with immunoglobulin use.
Which Region Provides Lucrative Opportunities for Market Players?
“Significant Reimbursement Coverage Boosting Market Value in North America”
North America accounts for 50% share of the global immunoglobulins market owing to the high prevalence of neurological, immunological, and other disorders, a rise in the local supply of intravenous immunoglobulin products, and significant reimbursement coverage along with the presence of major market players. New developments in antibody therapy, increased consumer awareness of personal health, and medical innovations are driving market growth in the region.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Insights
Why is the Adoption of Immunoglobulins Surging in the United States?
“Development of Plasma Biocentres in the Country”
Increasing consumer awareness of the medicines used to treat immunodeficiency illnesses and growing preference among physicians for immunodeficiency therapies are the main factors propelling market growth in the United States. The development of plasma biocentres, plasma collection sites, and specialized infusion facilities is anticipated to accelerate market expansion in the United States.
How is Germany Aiding Market Growth in Europe?
“Increasing Government Investments in Advanced Medical Therapies”
The market in Germany is anticipated to experience consistent revenue growth due to the growing adoption of immunoglobulin therapy among the median-age population. Increasing government investments in advanced medical therapies will fuel market expansion over the projection period.
Will Japan be an Investment-worthy Market for Immunoglobulin Producers?
“Growing Adoption of Blood & Plasma Collection Techniques”
Rapid development of healthcare infrastructure, growing adoption of blood and plasma collection techniques, and increasing geriatric population are the key drivers augmenting market growth in Japan. Rising R&D expenditures, the presence of plasma fractionation facilities, growing awareness of blood donation and its potential use in creating life-saving products, and rising disposable income are supporting market growth.
Category-wise Insights
Which Route of Administration is Forecast to Gain the Prominent Market Share?
“Intravenous Immunoglobulin Administration Preferred Due to High Effectiveness & Bioavailability”
By route of administration, the market is segmented into intravenous, subcutaneous, and intramuscular. Intravenous immunoglobulin administration accounts for 60% share of the global market owing to the rise in strategic initiatives involving intravenous immunoglobulin and the rapid absorption rate provided by intravenous delivery.
Approval of intravenous immunoglobulin (IVIG) products for chronic and rare diseases is projected to uplift the market. An injection or infusion form of drug administration into the vein by a needle or tube is referred to as an intravenous route of administration. A substance produced of antibodies that can be administered intravenously is called intravenous immunoglobulin.
The most popular type of immunoglobulin used to treat immunodeficiency and autoimmune illnesses is intravenous immunoglobulin (IVIG). Since immunoglobulins have been suggested for therapeutic use, they have been delivered intravenously, which offers high effectiveness and bioavailability.
Which Application Will Emerge as Key Market Contributor?
“Immunoglobulins Widely Used in Neurology Owing to Growing Prevalence of Rare Neurological Disorders”
Based on application, the market is divided into neurology, immunology, hematology, and others. High usage of immunoglobulins in neurology is attributed to the increasing prevalence of neurological conditions, including multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy (CIDP). Intravenous, subcutaneous and intramuscular immunoglobulins are effective for the treatment of rare neurological disorders.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Competitive Landscape
Leading companies are concentrating on molecular immunoglobulin indications and quality control of pipeline products following safety regulations to lower the environmental impact. To expand their presence in developing regions, key market players are focusing on supply chain management and enhancing product standards.
Top immunoglobulin producers are offering technologically advanced methods and platforms for a better understanding of disease biology and the introduction of innovative therapies. Top vendors in the industry need to obtain plasma for fractionation. Wide-spread installations of plasma collecting facilities can be made throughout the countries, enabling the collection of greater volumes of plasma.
For instance,
- Grifols S.A. manufactures Gamunex C and Flebogamma Intravenous immunoglobulin products. Gamunex C is a sterilized solution made from human plasma that contains antibodies to treat primary immunodeficiency.
- CSL Behring is engaged in producing subcutaneous immunoglobulin products such as Privigen, Evogam, and Beriglobin P. Berigloin P is presented in the form of an injection containing excipients of glycine, sodium chloride, hydrochloric acid, or sodium hydroxide and water.
- In 2019, the United States Food and Drug Administration granted Kedrion Biopharma permission to perform a clinical trial to evaluate the effectiveness and safety of a 10% intravenous immunoglobulin in the treatment of individuals with primary immunodeficiency illnesses.
- In 2022, the indication for Octapharma's cutaquig was enhanced by the European Union. It is a human immunoglobulin intended for subcutaneous use. Patients with any kind of secondary immunodeficiency who require immunoglobulin replacement therapy are covered by the expanded indication.
Key Segments of Immunoglobulins Industry Research
-
By Administration :
- Intravenous
- Subcutaneous
- Intramuscular
-
By Application :
- Neurology
- Immunology
- Hematology
- Others
-
By End User :
- Hospitals
- Clinics
- Homecare
-
By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Table of Content
1. Preface 1.1. Market Definition and Scope 1.2. Market Segmentation 1.3. Key Research Objectives 1.4. Research Highlights 2. Assumptions and Research Methodology 3. Executive Summary: Global Market 4. Market Overview 4.1. Introduction 4.1.1. Market Definition 4.1.2. Industry Evolution / Developments 4.2. Overview 4.3. Market Dynamics 4.3.1. Drivers 4.3.2. Restraints 4.3.3. Opportunities 4.4. Global Market Analysis and Forecast, 2023–2033 4.4.1. Global Market Value (US$ Mn) Projections 4.5. Porter’s Five Force Analysis 5. Market Outlook 5.1. Disease Prevalence & Incidence Rate Globally with Key Countries 5.2. Regulatory Scenario by Region/globally 5.3. Pipeline Analysis 6. Global Market Analysis and Forecast, by Applications 6.1. Introduction & Definition 6.2. Key Findings / Developments 6.3. Global Market Value Forecast, by Applications, 2023–2033 6.3.1. Neurology 6.3.2. Immunology 6.3.3. Hematology 6.3.4. Others 6.4. Global Market Attractiveness by Applications 7. Global Market Analysis and Forecast, by Route of Administration 7.1. Introduction & Definition 7.2. Key Findings / Developments 7.3. Global Market Value Forecast, by Route of Administration, 2023–2033 7.3.1. Intravenous 7.3.2. Subcutaneous 7.3.3. Intramuscular 7.4. Global Market Attractiveness by Route of Administration 8. Global Market Analysis and Forecast, by End-user 8.1. Introduction & Definition 8.2. Key Findings / Developments 8.3. Global Market Value Forecast, by End-user, 2023–2033 8.3.1. Hospital 8.3.2. Clinic 8.3.3. Homecare 8.4. Global Market Attractiveness by End-user 9. Global Market Analysis and Forecast, by Region 9.1. Key Findings 9.2. Global Market Value Forecast, by Region 9.2.1. North America 9.2.2. Europe 9.2.3. Asia Pacific 9.2.4. Latin America 9.2.5. Middle East & Africa 9.3. Global Market Attractiveness, by Country/Region 10. North America Market Analysis and Forecast 10.1. Introduction 10.1.1. Key Findings 10.2. North America Market Value Forecast, by Applications, 2023–2033 10.2.1. Neurology 10.2.2. Immunology 10.2.3. Hematology 10.2.4. Others 10.3. North America Market Value Forecast, by Route of Administration, 2023–2033 10.3.1. Intravenous 10.3.2. Subcutaneous 10.3.3. Intramuscular 10.4. North America Market Value Forecast, by End-user, 2023–2033 10.4.1. Hospital 10.4.2. Clinic 10.4.3. Homecare 10.5. North America Market Value Forecast, by Country, 2023–2033 10.5.1. US 10.5.2. Canada 10.6. North America Market Attractiveness Analysis 10.6.1. By Applications 10.6.2. By Route of Administration 10.6.3. By End-user 10.6.4. By Country 11. Europe Market Analysis and Forecast 11.1. Introduction 11.1.1. Key Findings 11.2. Europe Market Value Forecast by Applications, 2023–2033 11.2.1. Neurology 11.2.2. Immunology 11.2.3. Hematology 11.2.4. Others 11.3. Europe Market Value Forecast, by Route of Administration, 2023–2033 11.3.1. Intravenous 11.3.2. Subcutaneous 11.3.3. Intramuscular 11.4. Europe Market Value Forecast, by End-user, 2023–2033 11.4.1. Hospital 11.4.2. Clinic 11.4.3. Homecare 11.5. Europe Market Value Forecast, by Country/Sub-region, 2023–2033 11.5.1. Germany 11.5.2. France 11.5.3. U.K. 11.5.4. Italy 11.5.5. Spain 11.5.6. Rest of Europe 11.6. Europe Market Attractiveness Analysis 11.6.1. By Applications 11.6.2. By Route of Administration 11.6.3. By End-user 11.6.4. By Country/Sub-region 12. Asia Pacific Market Analysis and Forecast 12.1. Introduction 12.1.1. Key Findings 12.2. Asia Pacific Market Value Forecast, by Applications, 2023–2033 12.2.1. Neurology 12.2.2. Immunology 12.2.3. Hematology 12.2.4. Others 12.3. Asia Pacific Market Value Forecast, by Route of Administration, 2023–2033 12.3.1. Intravenous 12.3.2. Subcutaneous 12.3.3. Intramuscular 12.4. Asia Pacific Market Value Forecast, by End-user, 2023–2033 12.4.1. Hospital 12.4.2. Clinic 12.4.3. Homecare 12.5. Asia Pacific Market Value Forecast, by Country/Sub-region, 2023–2033 12.5.1. Japan 12.5.2. China 12.5.3. India 12.5.4. Australia & New Zealand 12.5.5. Rest of Asia Pacific 12.6. Asia Pacific Market Attractiveness Analysis 12.6.1. By Applications 12.6.2. By Route of Administration 12.6.3. By End-user 12.6.4. By Country/Sub-region 13. Latin America Market Analysis and Forecast 13.1. Introduction 13.1.1. Key Findings 13.2. Latin America Market Value Forecast, by Applications, 2023–2033 13.2.1. Neurology 13.2.2. Immunology 13.2.3. Hematology 13.2.4. Others 13.3. Latin America Market Value Forecast, by Route of Administration, 2023–2033 13.3.1. Intravenous 13.3.2. Subcutaneous 13.3.3. Intramuscular 13.4. Latin America Market Value Forecast, by End-user, 2023–2033 13.4.1. Hospital 13.4.2. Clinic 13.4.3. Homecare 13.5. Latin America Market Value Forecast, by Country/Sub-region, 2023–2033 13.5.1. Brazil 13.5.2. Mexico 13.5.3. Rest of Latin America 13.6. Latin America Market Attractiveness Analysis 13.6.1. By Applications 13.6.2. By Route of Administration 13.6.3. By End-user 13.6.4. By Country/Sub-region 14. Middle East & Africa Market Analysis and Forecast 14.1. Introduction 14.1.1. Key Findings 14.2. Latin America Market Value Forecast, by Applications, 2023–2033 14.2.1. Neurology 14.2.2. Immunology 14.2.3. Hematology 14.2.4. Others 14.3. Latin America Market Value Forecast, by Route of Administration, 2023–2033 14.3.1. Intravenous 14.3.2. Subcutaneous 14.3.3. Intramuscular 14.4. Latin America Market Value Forecast, by End-user, 2023–2033 14.4.1. Hospital 14.4.2. Clinic 14.4.3. Homecare 14.5. Latin America Market Value Forecast, by Country/Sub-region, 2023–2033 14.5.1. GCC Countries 14.5.2. South Africa 14.5.3. Rest of Middle East & Africa 14.6. Latin America Market Attractiveness Analysis 14.6.1. By Applications 14.6.2. By Route of Administration 14.6.3. By End-user 14.6.4. By Country/Sub-region 15. Competition Landscape 15.1. Market Player – Competition Matrix (by Tier and Size of companies) 15.2. Market Share Analysis by Company (2022) 15.3. Company Profiles 15.3.1. Shire 15.3.2. CSL Behring 15.3.3. Kedrion Biopharma Inc 15.3.4. Grifols, S.A. 15.3.5. Octapharma 15.3.6. China Biologic Products Holdings, Inc 15.3.7. Biotest AG 15.3.8. Sanquin 15.3.9. LFB SA
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 02: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 03: Global Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 04: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033
Table 05: North America Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 06: North America Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 07: North America Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 08: North America Market Value (US$ Mn) Forecast, by Country, 2023–2033
Table 09: Europe Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 10 Europe Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 11: Europe Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 12: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 13: Asia Pacific Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 14: Asia Pacific Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 15: Asia Pacific Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 16: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 17: Latin America Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 18: Latin America Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 19: Latin America Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 20: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
Table 21: Middle East & Africa Value (US$ Mn) Forecast, by Applications, 2023–2033
Table 22: Middle East & Africa Value (US$ Mn) Forecast, by Route of Administration, 2023–2033
Table 23: Middle East & Africa Market Value (US$ Mn) Forecast, by End-user, 2023–2033
Table 24: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Snapshot
Figure 02: Global Market Value (US$ Mn) and Distribution, by Region, 2023 and 2033
Figure 03: Global Market Snapshot, ROA
Figure 04: Global Market Snapshot, ROA
Figure 05: Global Market Value (US$ Mn) Forecast, 2023?2033
Figure 06: Global Market Value Share, by Applications (2022)
Figure 07: Global Market Value Share, by Route of Administration (2022)
Figure 08: Global Market Value Share, by End-user (2022)
Figure 09: Global Market Value Share, by Region (2022)
Figure 10: Global Market Value Share Analysis, by Applications, 2023 and 2033
Figure 11: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Neurology, 2023–2033
Figure 12: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hematology, 2023–2033
Figure 13: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Others, 2022-2033
Figure 14: Global Market Attractiveness, by Applications, 2023–2033
Figure 15: Global Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 16: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Subcutaneous, 2023–2033
Figure 17: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intramuscular, 2023–2033
Figure 18: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intravenous, 2023–2033
Figure 19: Global Market Attractiveness, by Route of Administration, 2023–2033
Figure 20: Global Market Value Share (%), by End-user, 2023 and 2033
Figure 22: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Clinic, 2023–2033
Figure 23: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Homecare, 2023–2033
Figure 21: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital, 2023–2033
Figure 24: Global Market Attractiveness, by End-user, 2023–2033
Figure 25: Global Market Value Share Analysis, by Region 2023 and 2033
Figure 26: Global Market Attractiveness, by Region, 2023–2033
Figure 27: North America Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 28: North America Market Value Share (%), by Applications, 2023 and 2033
Figure 29: North America Market Attractiveness, by Applications, 2023–2033
Figure 30: North America Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 31: North America Market Attractiveness, by Route of Administration, 2023–2033
Figure 32: North America Market Value Share (%), by End-user, 2023 and 2033
Figure 33: North America Market Attractiveness, by End-user, 2023–2033
Figure 34: North America Market Value Share (%), by Country, 2023 and 2033
Figure 35: North America Market Attractiveness, by Country, 2023–2033
Figure 36: Europe Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 37: Europe Market Value Share (%), by Applications, 2023 and 2033
Figure 38: Europe Market Attractiveness, by Applications, 2023–2033
Figure 39: Europe Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 40: Europe Market Attractiveness, by Route of Administration, 2023–2033
Figure 41: Europe Market Value Share (%), by End-user, 2023 and 2033
Figure 42: Europe Market Attractiveness, by End-user, 2023–2033
Figure 43: Europe Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 44: Europe Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 45: Latin America Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 46: Asia Pacific Market Value Share (%), by Applications, 2023 and 2033
Figure 47: Asia Pacific Market Attractiveness, by Applications, 2023–2033
Figure 48: Asia Pacific Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 49: Asia Pacific Market Attractiveness, by Route of Administration, 2023–2033
Figure 50: Asia Pacific Market Value Share (%), by End-user, 2023 and 2033
Figure 51: Asia Pacific Market Attractiveness, by End-user, 2023–2033
Figure 52: Asia Pacific Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 53: Asia Pacific Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 54: Latin America Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 55: Latin America Market Value Share (%), by Applications, 2023 and 2033
Figure 56: Latin America Market Attractiveness, by Applications, 2023–2033
Figure 57: Latin America Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 58: Latin America Market Attractiveness, by Route of Administration, 2023–2033
Figure 59: Latin America Market Value Share (%), by End-user, 2023 and 2033
Figure 60: Latin America Market Attractiveness, by End-user, 2023–2033
Figure 61: Latin America Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 62: Latin America Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 63: Middle East & Africa Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, 2023–2033
Figure 64: Middle East & Africa Market Value Share (%), by Applications, 2023 and 2033
Figure 65 Middle East & Africa Market Attractiveness, by Applications, 2023–2033
Figure 66: Middle East & Africa Market Value Share (%), by Route of Administration, 2023 and 2033
Figure 67: Middle East & Africa Market Attractiveness, by Route of Administration, 2023–2033
Figure 68: Middle East & Africa Market Value Share (%), by End-user, 2023 and 2033
Figure 69: Middle East & Africa Market Attractiveness, by End-user, 2023–2033
Figure 70: Middle East & Africa Market Value Share (%), by Country/Sub-region, 2023 and 2033
Figure 71: Middle East & Africa Market Attractiveness, by Country/Sub-region, 2023–2033
Figure 72: Global Market Share Analysis, by Company (2022)
Figure 73: Research & Development Expenses (2022)
Figure 74: Breakdown of Net Sales (% Share), by Region (2022)
Figure 75: Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2022
Figure 76: Breakdown of Net Sales (% Share), by Business Segment (2022)
Figure 77: Research and Development Expenses, 2014–2022
Figure 78: Breakdown of Net Sales (% Share), by Region (2022–2022)
Figure 79: Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2022
Figure 80: Research and Development Expenses, 2015-2022
Figure 81: Breakdown of Net Sales (% Share), by Region (2022)
Figure 82: Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2022
Figure 83: Breakdown of Net Sales (% Share), by Business Segment (2022)
Figure 84: Research and Development Expenses, 2015-2022
Figure 85: Breakdown of Net Sales (% Share), by Region (2022)
Figure 86: Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2022
Figure 87: Breakdown of Net Sales (% Share), by Business Segment (2022)
Figure 88: Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2022
Figure 89: Research and Development Expenses, 2015-2022
Figure 90: Breakdown of Net Sales, by Business Segment, 2022
Figure 91: Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2022
Figure 92: Research & Development Cost, 2015–2022 (US$ Mn)
Figure 93: Breakdown of Net Sales, by Business Segment, 2022
Figure 94: Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2022
Figure 95: Research & Development Cost, 2015–2022 (US$ Mn)
Figure 96: Breakdown of Net Sales, by Business Segment, 2022
Figure 97: Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2022
Figure 98: Research & Development Cost, 2015–2022 (US$ Mn)
Figure 99: Breakdown of Net Sales, by Business Segment, 2022
Figure 100: Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2022
Figure 101: Research & Development Cost, 2015–2022 (US$ Mn)
Figure 102: Breakdown of Net Sales, by Business Segment, 2022
Figure 103: Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2022
Figure 104: Research & Development Cost, 2015–2022 (US$ Mn)
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the predicted growth rate of the immunoglobulins market?
The global immunoglobulins market is estimated to rise at a CAGR of 6.8% through 2033.
Which are the major companies operating in the immunoglobulins market?
Grifols, S.A., Octapharma, and Kedrion Biopharma Inc. are key providers of immunoglobulins.
Which is the most dominant regional market for immunoglobulins?
North America accounts for 50% share of the global immunoglobulins market.
How big will the market for immunoglobulins be by 2033?
By 2033-end, the immunoglobulins market is expected to reach a valuation of US$ 27 billion.
Which key factor is driving the demand for immunoglobulins?
Rapid adoption of immunoglobulins due to increased safety and effective treatment outcomes is fueling market expansion.
Immunoglobulins Market